ARTICLE | Finance
Ebb & Flow
December 7, 2009 8:00 AM UTC
The latest follow-on from Human Genome Sciences Inc. (NASDAQ:HGSI) will increase its cash to around $1.1 billion, more than enough to get Benlysta belimumab to market for systemic lupus erythematosus.
Indeed, if all goes well, the company won't need the cash to pay for its $400 million in convertible debt, which is well in the money...